AUPH Aurinia Pharmaceuticals, Inc.

6.41-0.18 (-2.73%)
Close: September 16, 2019

6.410.00 (+0.02%)
After hours

Quote

Previous Close
$6.41
Day Range
$6.30-$6.60
52 Week Range
$5.06-$7.85
Volume
3,180,137
Avg Volume
623,319
Dividend TTM
-
Ex-Dividend Date
-

Valuation

Market Cap
$588.63M
Enterprise Value (EV)
$479.30M
PE Ratio
-
EV/EBITDA
-8.78
Price/Sales
-
Price/Book
5.23
PEG Ratio
0.46

Financials

Revenue
-
Gross Profit
-
EBITDA
-$54.59M
EPS, ttm
-$0.70
Profit Margin
-
Revenue/Employee
-
Next Earnings Date
11/11/2019 (55 days)
Debt to Equity
-
Debt
$16.53M
Cash
$125.86M
Net Debt
-

Performance

Beta
0.96
200 Day Moving Avg
$6.34
50 Day Moving Avg
$6.07
52 Week Change
16.55%
YTD Change
-6.39%
1 Month Change
11.69%
3 Month Change
3.94%
6 Month Change
5.10%
1 Year Change
19.82%
2 Year Change
-10.04%
5 Year Change
91.30%

Share Count

Shares Outstanding
91.8M
Float
61.4M
Restricted Shares
30.4M
Restricted Shares, %
33.13%

Aurinia Pharmaceuticals, Inc. Company Details

Sector: Health Technology

Industry: Biotechnology

CEO: Peter S. Greenleaf

Website: http://www.auriniapharma.com

Description: Aurinia Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of a therapeutic drug to treat autoimmune diseases particularly lupus nephritis. The company was founded by Robert Foster, Richard Glickman and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.

Employees: 39